AU2022390088B2 - Compounds for treating mds-associated anemias and other conditions - Google Patents

Compounds for treating mds-associated anemias and other conditions

Info

Publication number
AU2022390088B2
AU2022390088B2 AU2022390088A AU2022390088A AU2022390088B2 AU 2022390088 B2 AU2022390088 B2 AU 2022390088B2 AU 2022390088 A AU2022390088 A AU 2022390088A AU 2022390088 A AU2022390088 A AU 2022390088A AU 2022390088 B2 AU2022390088 B2 AU 2022390088B2
Authority
AU
Australia
Prior art keywords
week
subject
mds
weeks
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022390088A
Other languages
English (en)
Other versions
AU2022390088A1 (en
Inventor
Vanessa BEYNON
Suman Joy BHATIA
Lenny Dang
Melissa L. DIBACCO
Varsha V. IYER
Chi-yun Charles KUNG
Megan LYNCH
Rolandas URBSTONAITIS
Zhen Xiao
Ophelia Qiping Yin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agios Pharmaceuticals Inc
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of AU2022390088A1 publication Critical patent/AU2022390088A1/en
Application granted granted Critical
Publication of AU2022390088B2 publication Critical patent/AU2022390088B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2022390088A 2021-11-16 2022-11-15 Compounds for treating mds-associated anemias and other conditions Active AU2022390088B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163280069P 2021-11-16 2021-11-16
US63/280,069 2021-11-16
US202263357240P 2022-06-30 2022-06-30
US63/357,240 2022-06-30
PCT/US2022/049969 WO2023091414A1 (en) 2021-11-16 2022-11-15 Compounds for treating mds-associated anemias and other conditions

Publications (2)

Publication Number Publication Date
AU2022390088A1 AU2022390088A1 (en) 2024-05-09
AU2022390088B2 true AU2022390088B2 (en) 2026-07-02

Family

ID=84887868

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022390088A Active AU2022390088B2 (en) 2021-11-16 2022-11-15 Compounds for treating mds-associated anemias and other conditions

Country Status (11)

Country Link
US (1) US20250108049A1 (cg-RX-API-DMAC7.html)
EP (1) EP4433057A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024543345A (cg-RX-API-DMAC7.html)
KR (1) KR20240107326A (cg-RX-API-DMAC7.html)
AU (1) AU2022390088B2 (cg-RX-API-DMAC7.html)
CA (1) CA3236880A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001431A1 (cg-RX-API-DMAC7.html)
IL (1) IL312679A (cg-RX-API-DMAC7.html)
MX (1) MX2024005852A (cg-RX-API-DMAC7.html)
TW (1) TW202329935A (cg-RX-API-DMAC7.html)
WO (1) WO2023091414A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024238659A1 (en) * 2023-05-15 2024-11-21 Agios Pharmaceuticals, Inc. Crystalline salts or amorphous forms of 2-((1h-pyrazol-3-yl)methyl)-6-((6-aminopyridin-2-yl)methyl)-4-methyl-4,6-dihydro -5h-thiazolo[5',4':4,5]pyrrolo[2,3-d]pyridazin-5-one
WO2026076363A1 (en) 2024-10-04 2026-04-09 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019035864A1 (en) * 2017-08-15 2019-02-21 Agios Pharmaceuticals, Inc. PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120693A1 (es) 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
MX384883B (es) 2015-06-11 2025-03-14 Agios Pharmaceuticals Inc Métodos para usar activadores de piruvato cinasa.
KR102682430B1 (ko) 2017-11-22 2024-07-08 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의 결정 형태
JP2022533227A (ja) 2019-05-22 2022-07-21 アジオス ファーマシューティカルズ, インコーポレイテッド N-(4-(4-(シクロプロピルメチル)ピペラジン-1-カルボニル)フェニル)キノリン-8-スルホンアミドの結晶性塩形態

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019035864A1 (en) * 2017-08-15 2019-02-21 Agios Pharmaceuticals, Inc. PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Grace, R.F. et al., 'Management of pyruvate kinase deficiency in children and adults', Blood - The American Society of Hematology. 2020, vol.136, pages 1241-1249 *

Also Published As

Publication number Publication date
WO2023091414A1 (en) 2023-05-25
AU2022390088A1 (en) 2024-05-09
KR20240107326A (ko) 2024-07-09
CA3236880A1 (en) 2023-05-25
MX2024005852A (es) 2024-05-28
CL2024001431A1 (es) 2024-10-25
JP2024543345A (ja) 2024-11-21
US20250108049A1 (en) 2025-04-03
EP4433057A1 (en) 2024-09-25
IL312679A (en) 2024-07-01
TW202329935A (zh) 2023-08-01

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ BEYNON, VANESSA; BHATIA, SUMAN, JOY; DANG, LENNY; DIBACCO, MELISSA, L.; IYER, VARSHA, V.; KUNG, CHI-YUN CHARLES; LYNCH, MEGAN; YIN, OPHELIA QIPING; URBSTONAITIS, ROLANDAS AND XIAO, ZHEN